Compile Data Set for Download or QSAR
Report error Found 467 Enz. Inhib. hit(s) with all data for entry = 3332
TargetEpidermal growth factor receptor(Human)
Celgene Car

US Patent
LigandPNGBDBM397267(US9987276, Compound I-248 | US10596172, Compound I...)
Affinity DataIC50: 10nMAssay Description:EGFR (WT) and EGFR (T790M/L858R): The Omnia Assay Protocol for potency assessment against EGFR is performed as described in Example 251 above except ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/25/2020
Entry Details
US Patent

TargetTyrosine-protein kinase ITK/TSK(Human)
Celgene Car

US Patent
LigandPNGBDBM397254(US9987276, Compound I-218 | US10596172, Compound I...)
Affinity DataIC50: 10nMAssay Description:ITK: This example describes continuous-read kinase assays to measure inherent potency of compound against active forms of ITK enzymes as described in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/25/2020
Entry Details
US Patent

TargetTyrosine-protein kinase ITK/TSK(Human)
Celgene Car

US Patent
LigandPNGBDBM397248(US9987276, Compound I-207 | US10596172, Compound I...)
Affinity DataIC50: 10nMAssay Description:ITK: This example describes continuous-read kinase assays to measure inherent potency of compound against active forms of ITK enzymes as described in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/25/2020
Entry Details
US Patent

TargetTyrosine-protein kinase ITK/TSK(Human)
Celgene Car

US Patent
LigandPNGBDBM397250(US9987276, Compound I-209 | US10596172, Compound I...)
Affinity DataIC50: 10nMAssay Description:ITK: This example describes continuous-read kinase assays to measure inherent potency of compound against active forms of ITK enzymes as described in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/25/2020
Entry Details
US Patent

TargetEpidermal growth factor receptor(Human)
Celgene Car

US Patent
LigandPNGBDBM397265(US9987276, Compound I-245 | US10596172, Compound I...)
Affinity DataIC50: 10nMAssay Description:EGFR (WT) and EGFR (T790M/L858R): The Omnia Assay Protocol for potency assessment against EGFR is performed as described in Example 251 above except ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/25/2020
Entry Details
US Patent

TargetTyrosine-protein kinase ITK/TSK(Human)
Celgene Car

US Patent
LigandPNGBDBM397240(US9987276, Compound I-194 | US10596172, Compound I...)
Affinity DataIC50: 10nMAssay Description:ITK: This example describes continuous-read kinase assays to measure inherent potency of compound against active forms of ITK enzymes as described in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/25/2020
Entry Details
US Patent

TargetEpidermal growth factor receptor(Human)
Celgene Car

US Patent
LigandPNGBDBM397260(US9987276, Compound I-233 | US10596172, Compound I...)
Affinity DataIC50: 10nMAssay Description:EGFR (WT) and EGFR (T790M/L858R): The Omnia Assay Protocol for potency assessment against EGFR is performed as described in Example 251 above except ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/25/2020
Entry Details
US Patent

TargetTyrosine-protein kinase ITK/TSK(Human)
Celgene Car

US Patent
LigandPNGBDBM397265(US9987276, Compound I-245 | US10596172, Compound I...)
Affinity DataIC50: 10nMAssay Description:ITK: This example describes continuous-read kinase assays to measure inherent potency of compound against active forms of ITK enzymes as described in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/25/2020
Entry Details
US Patent

TargetTyrosine-protein kinase ITK/TSK(Human)
Celgene Car

US Patent
LigandPNGBDBM397267(US9987276, Compound I-248 | US10596172, Compound I...)
Affinity DataIC50: 10nMAssay Description:ITK: This example describes continuous-read kinase assays to measure inherent potency of compound against active forms of ITK enzymes as described in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/25/2020
Entry Details
US Patent

TargetEpidermal growth factor receptor(Human)
Celgene Car

US Patent
LigandPNGBDBM397373(US9987276, Compound I-328 | US10596172, Compound I...)
Affinity DataIC50: 10nMAssay Description:EGFR (WT) and EGFR (T790M/L858R): The Omnia Assay Protocol for potency assessment against EGFR is performed as described in Example 251 above except ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/25/2020
Entry Details
US Patent

TargetTyrosine-protein kinase ITK/TSK(Human)
Celgene Car

US Patent
LigandPNGBDBM397260(US9987276, Compound I-233 | US10596172, Compound I...)
Affinity DataIC50: 10nMAssay Description:ITK: This example describes continuous-read kinase assays to measure inherent potency of compound against active forms of ITK enzymes as described in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/25/2020
Entry Details
US Patent

TargetTyrosine-protein kinase ITK/TSK(Human)
Celgene Car

US Patent
LigandPNGBDBM397261(US9987276, Compound I-237 | US10596172, Compound I...)
Affinity DataIC50: 10nMAssay Description:ITK: This example describes continuous-read kinase assays to measure inherent potency of compound against active forms of ITK enzymes as described in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/25/2020
Entry Details
US Patent

TargetTyrosine-protein kinase ITK/TSK(Human)
Celgene Car

US Patent
LigandPNGBDBM397262(US9987276, Compound I-242 | US10596172, Compound I...)
Affinity DataIC50: 10nMAssay Description:ITK: This example describes continuous-read kinase assays to measure inherent potency of compound against active forms of ITK enzymes as described in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/25/2020
Entry Details
US Patent

TargetTyrosine-protein kinase ITK/TSK(Human)
Celgene Car

US Patent
LigandPNGBDBM397257(US9987276, Compound I-227 | US10596172, Compound I...)
Affinity DataIC50: 10nMAssay Description:ITK: This example describes continuous-read kinase assays to measure inherent potency of compound against active forms of ITK enzymes as described in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/25/2020
Entry Details
US Patent

TargetTyrosine-protein kinase ITK/TSK(Human)
Celgene Car

US Patent
LigandPNGBDBM397259(US9987276, Compound I-230 | US10596172, Compound I...)
Affinity DataIC50: 10nMAssay Description:ITK: This example describes continuous-read kinase assays to measure inherent potency of compound against active forms of ITK enzymes as described in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/25/2020
Entry Details
US Patent

TargetTyrosine-protein kinase ITK/TSK(Human)
Celgene Car

US Patent
LigandPNGBDBM397286(US9987276, Compound I-359 | US10596172, Compound I...)
Affinity DataIC50: 10nMAssay Description:ITK: This example describes continuous-read kinase assays to measure inherent potency of compound against active forms of ITK enzymes as described in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/25/2020
Entry Details
US Patent

TargetEpidermal growth factor receptor(Human)
Celgene Car

US Patent
LigandPNGBDBM397388(US9987276, Compound I-350 | US10596172, Compound I...)
Affinity DataIC50: 10nMAssay Description:EGFR (WT) and EGFR (T790M/L858R): The Omnia Assay Protocol for potency assessment against EGFR is performed as described in Example 251 above except ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/25/2020
Entry Details
US Patent

TargetTyrosine-protein kinase ITK/TSK(Human)
Celgene Car

US Patent
LigandPNGBDBM397276(US9987276, Compound I-329 | US10596172, Compound I...)
Affinity DataIC50: 10nMAssay Description:ITK: This example describes continuous-read kinase assays to measure inherent potency of compound against active forms of ITK enzymes as described in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/25/2020
Entry Details
US Patent

TargetEpidermal growth factor receptor(Human)
Celgene Car

US Patent
LigandPNGBDBM397379(US9987276, Compound I-339 | US10596172, Compound I...)
Affinity DataIC50: 10nMAssay Description:EGFR (WT) and EGFR (T790M/L858R): The Omnia Assay Protocol for potency assessment against EGFR is performed as described in Example 251 above except ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/25/2020
Entry Details
US Patent

TargetEpidermal growth factor receptor(Human)
Celgene Car

US Patent
LigandPNGBDBM397377(US9987276, Compound I-334 | US10596172, Compound I...)
Affinity DataIC50: 10nMAssay Description:EGFR (WT) and EGFR (T790M/L858R): The Omnia Assay Protocol for potency assessment against EGFR is performed as described in Example 251 above except ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/25/2020
Entry Details
US Patent

TargetTyrosine-protein kinase ITK/TSK(Human)
Celgene Car

US Patent
LigandPNGBDBM397274(US9987276, Compound I-322 | US10596172, Compound I...)
Affinity DataIC50: 10nMAssay Description:ITK: This example describes continuous-read kinase assays to measure inherent potency of compound against active forms of ITK enzymes as described in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/25/2020
Entry Details
US Patent

TargetEpidermal growth factor receptor(Human)
Celgene Car

US Patent
LigandPNGBDBM397378(US9987276, Compound I-335 | US10596172, Compound I...)
Affinity DataIC50: 10nMAssay Description:EGFR (WT) and EGFR (T790M/L858R): The Omnia Assay Protocol for potency assessment against EGFR is performed as described in Example 251 above except ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/25/2020
Entry Details
US Patent

TargetTyrosine-protein kinase ITK/TSK(Human)
Celgene Car

US Patent
LigandPNGBDBM397275(US9987276, Compound I-324 | US10596172, Compound I...)
Affinity DataIC50: 10nMAssay Description:ITK: This example describes continuous-read kinase assays to measure inherent potency of compound against active forms of ITK enzymes as described in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/25/2020
Entry Details
US Patent

TargetCytoplasmic tyrosine-protein kinase BMX(Human)
Celgene Car

US Patent
LigandPNGBDBM397192(US9987276, Compound I-129 | US10596172, Compound I...)
Affinity DataIC50: 10nMAssay Description:BMX: The activity of selected compounds of this invention in the BMX inhibition assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
4/25/2020
Entry Details
US Patent

TargetEpidermal growth factor receptor [T790M,L858R](Human)
Celgene Car

US Patent
LigandPNGBDBM397143(US9987276, Compound I-2 | US10596172, Compound I-8...)
Affinity DataIC50: 10nMAssay Description:EGFR (WT) and EGFR (T790M/L858R): The Omnia Assay Protocol for potency assessment against EGFR is performed as described in Example 251 above except ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/25/2020
Entry Details
US Patent

TargetCytoplasmic tyrosine-protein kinase BMX(Human)
Celgene Car

US Patent
LigandPNGBDBM397193(US9987276, Compound I-131 | US10596172, Compound I...)
Affinity DataIC50: 10nMAssay Description:BMX: The activity of selected compounds of this invention in the BMX inhibition assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
4/25/2020
Entry Details
US Patent

TargetEpidermal growth factor receptor [T790M](Human)
Celgene Car

US Patent
LigandPNGBDBM397143(US9987276, Compound I-2 | US10596172, Compound I-8...)
Affinity DataIC50: 10nMAssay Description:EGFR (WT) and EGFR (T790M/L858R): The Omnia Assay Protocol for potency assessment against EGFR is performed as described in Example 251 above except ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/25/2020
Entry Details
US Patent

TargetCytoplasmic tyrosine-protein kinase BMX(Human)
Celgene Car

US Patent
LigandPNGBDBM397194(US9987276, Compound I-133 | US9987276, Compound I-...)
Affinity DataIC50: 10nMAssay Description:BMX: The activity of selected compounds of this invention in the BMX inhibition assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
4/25/2020
Entry Details
US Patent

TargetEpidermal growth factor receptor [T790M,L858R](Human)
Celgene Car

US Patent
LigandPNGBDBM397288(US9987276, Compound I-3 | US10596172, Compound I-3...)
Affinity DataIC50: 10nMAssay Description:EGFR (WT) and EGFR (T790M/L858R): The Omnia Assay Protocol for potency assessment against EGFR is performed as described in Example 251 above except ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/25/2020
Entry Details
US Patent

TargetCytoplasmic tyrosine-protein kinase BMX(Human)
Celgene Car

US Patent
LigandPNGBDBM397195(US9987276, Compound I-134 | US10596172, Compound I...)
Affinity DataIC50: 10nMAssay Description:BMX: The activity of selected compounds of this invention in the BMX inhibition assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
4/25/2020
Entry Details
US Patent

TargetEpidermal growth factor receptor [T790M](Human)
Celgene Car

US Patent
LigandPNGBDBM397288(US9987276, Compound I-3 | US10596172, Compound I-3...)
Affinity DataIC50: 10nMAssay Description:EGFR (WT) and EGFR (T790M/L858R): The Omnia Assay Protocol for potency assessment against EGFR is performed as described in Example 251 above except ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/25/2020
Entry Details
US Patent

TargetCytoplasmic tyrosine-protein kinase BMX(Human)
Celgene Car

US Patent
LigandPNGBDBM397152(US9987276, Compound I-40 | US10596172, Compound I-...)
Affinity DataIC50: 10nMAssay Description:BMX: The activity of selected compounds of this invention in the BMX inhibition assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
4/25/2020
Entry Details
US Patent

TargetCytoplasmic tyrosine-protein kinase BMX(Human)
Celgene Car

US Patent
LigandPNGBDBM397153(US9987276, Compound I-45 | US10596172, Compound I-...)
Affinity DataIC50: 10nMAssay Description:BMX: The activity of selected compounds of this invention in the BMX inhibition assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
4/25/2020
Entry Details
US Patent

TargetEpidermal growth factor receptor(Human)
Celgene Car

US Patent
LigandPNGBDBM397144(US9987276, Compound I-4 | US9987276, Compound I-36...)
Affinity DataIC50: 10nMAssay Description:EGFR (WT) and EGFR (T790M/L858R): The Omnia Assay Protocol for potency assessment against EGFR is performed as described in Example 251 above except ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/25/2020
Entry Details
US Patent

TargetCytoplasmic tyrosine-protein kinase BMX(Human)
Celgene Car

US Patent
LigandPNGBDBM397190(US9987276, Compound I-126 | US10596172, Compound I...)
Affinity DataIC50: 10nMAssay Description:BMX: The activity of selected compounds of this invention in the BMX inhibition assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
4/25/2020
Entry Details
US Patent

TargetCytoplasmic tyrosine-protein kinase BMX(Human)
Celgene Car

US Patent
LigandPNGBDBM397191(US9987276, Compound I-128 | US10596172, Compound I...)
Affinity DataIC50: 10nMAssay Description:BMX: The activity of selected compounds of this invention in the BMX inhibition assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
4/25/2020
Entry Details
US Patent

TargetEpidermal growth factor receptor [T790M,L858R](Human)
Celgene Car

US Patent
LigandPNGBDBM397142(US9987276, Compound I-1 | US10596172, Compound I-1...)
Affinity DataIC50: 10nMAssay Description:EGFR (WT) and EGFR (T790M/L858R): The Omnia Assay Protocol for potency assessment against EGFR is performed as described in Example 251 above except ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/25/2020
Entry Details
US Patent

TargetCytoplasmic tyrosine-protein kinase BMX(Human)
Celgene Car

US Patent
LigandPNGBDBM397148(US9987276, Compound I-33 | US10596172, Compound I-...)
Affinity DataIC50: 10nMAssay Description:BMX: The activity of selected compounds of this invention in the BMX inhibition assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
4/25/2020
Entry Details
US Patent

TargetCytoplasmic tyrosine-protein kinase BMX(Human)
Celgene Car

US Patent
LigandPNGBDBM397149(US9987276, Compound I-35 | US10596172, Compound I-...)
Affinity DataIC50: 10nMAssay Description:BMX: The activity of selected compounds of this invention in the BMX inhibition assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
4/25/2020
Entry Details
US Patent

TargetCytoplasmic tyrosine-protein kinase BMX(Human)
Celgene Car

US Patent
LigandPNGBDBM397150(US9987276, Compound I-38 | US10596172, Compound I-...)
Affinity DataIC50: 10nMAssay Description:BMX: The activity of selected compounds of this invention in the BMX inhibition assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
4/25/2020
Entry Details
US Patent

TargetCytoplasmic tyrosine-protein kinase BMX(Human)
Celgene Car

US Patent
LigandPNGBDBM397151(US9987276, Compound I-39 | US10596172, Compound I-...)
Affinity DataIC50: 10nMAssay Description:BMX: The activity of selected compounds of this invention in the BMX inhibition assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
4/25/2020
Entry Details
US Patent

TargetCytoplasmic tyrosine-protein kinase BMX(Human)
Celgene Car

US Patent
LigandPNGBDBM397144(US9987276, Compound I-4 | US9987276, Compound I-36...)
Affinity DataIC50: 10nMAssay Description:BMX: The activity of selected compounds of this invention in the BMX inhibition assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
4/25/2020
Entry Details
US Patent

TargetCytoplasmic tyrosine-protein kinase BMX(Human)
Celgene Car

US Patent
LigandPNGBDBM397145(US9987276, Compound I-7 | US10596172, Compound I-7...)
Affinity DataIC50: 10nMAssay Description:BMX: The activity of selected compounds of this invention in the BMX inhibition assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
4/25/2020
Entry Details
US Patent

TargetEpidermal growth factor receptor(Human)
Celgene Car

US Patent
LigandPNGBDBM397390(US9987276, Compound I-352 | US10596172, Compound I...)
Affinity DataIC50: 10nMAssay Description:EGFR (WT) and EGFR (T790M/L858R): The Omnia Assay Protocol for potency assessment against EGFR is performed as described in Example 251 above except ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/25/2020
Entry Details
US Patent

TargetCytoplasmic tyrosine-protein kinase BMX(Human)
Celgene Car

US Patent
LigandPNGBDBM397146(US9987276, Compound I-27 | US10596172, Compound I-...)
Affinity DataIC50: 10nMAssay Description:BMX: The activity of selected compounds of this invention in the BMX inhibition assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
4/25/2020
Entry Details
US Patent

TargetCytoplasmic tyrosine-protein kinase BMX(Human)
Celgene Car

US Patent
LigandPNGBDBM397147(US9987276, Compound I-28 | US10596172, Compound I-...)
Affinity DataIC50: 10nMAssay Description:BMX: The activity of selected compounds of this invention in the BMX inhibition assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
4/25/2020
Entry Details
US Patent

TargetEpidermal growth factor receptor [T790M,L858R](Human)
Celgene Car

US Patent
LigandPNGBDBM397156(US9987276, Compound I-56 | US10596172, Compound I-...)
Affinity DataIC50: 10nMAssay Description:EGFR (WT) and EGFR (T790M/L858R): The Omnia Assay Protocol for potency assessment against EGFR is performed as described in Example 251 above except ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/25/2020
Entry Details
US Patent

TargetEpidermal growth factor receptor(Human)
Celgene Car

US Patent
LigandPNGBDBM397293(US9987276, Compound I-11 | US10596172, Compound I-...)
Affinity DataIC50: 10nMAssay Description:EGFR (WT) and EGFR (T790M/L858R): The Omnia Assay Protocol for potency assessment against EGFR is performed as described in Example 251 above except ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/25/2020
Entry Details
US Patent

TargetEpidermal growth factor receptor [T790M,L858R](Human)
Celgene Car

US Patent
LigandPNGBDBM397173(US9987276, Compound I-96 | US10596172, Compound I-...)
Affinity DataIC50: 10nMAssay Description:EGFR (WT) and EGFR (T790M/L858R): The Omnia Assay Protocol for potency assessment against EGFR is performed as described in Example 251 above except ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/25/2020
Entry Details
US Patent

TargetEpidermal growth factor receptor(Human)
Celgene Car

US Patent
LigandPNGBDBM397144(US9987276, Compound I-4 | US9987276, Compound I-36...)
Affinity DataIC50: 10nMAssay Description:EGFR (WT) and EGFR (T790M/L858R): The Omnia Assay Protocol for potency assessment against EGFR is performed as described in Example 251 above except ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/25/2020
Entry Details
US Patent

Displayed 1 to 50 (of 467 total ) | Next | Last >>
Jump to: